WAI Kit Cheng, LAM Man Wa, SIN Lai Fong, CHAN Kin Iong, WONG Heong Ting, XIAO gang, WENJian Ming
Objective To explore the relationship
between PD-L1(SP142) and CTLA-4, PTEN expression in triple-negative breast cancer (TNBC). Methods One hundred and thirty six cases of breast
cancer were collected in Kiang Wu Hospital of Macau from January 2008 to June 2018, and divided into 4 groups according to molecular
classification,including TNBC, Luminal A, Luminal B and HER2-enriched. Expressions of PD-L1(SP142), CTLA-4 and PTEN were detected by immunohistochemical staining in the breast cancers.
The relationship between
PD-L1(SP142) expression and CTLA-4, PTEN expression were analyzed in TNBC and other molecular types of breast cancer. Results Among the 136 cases of breast cancer,
32.4% of cases were PD-L1(SP142) positive, in which, 48%
(24/50) TNBC, 11.9% (5/42)
Luminal A , 20% (3/15) Luminal B and 41.4% (12/29) HER2-enriched were PD-L1(SP142) positive. Among the 136 cases of breast cancer, 43.4% of cases were
CTLA-4 positive, in which, 52.0% (26/50)
TNBC, 31.0% (13/42) Luminal A, 33.3% (5/15) Luminal B and 50.9%
(15/29) HER2-enriched were CTLA-4 positive. Among the 136 cases of breast cancer, 28.0%
of cases
were PTEN positive, in which,
52.0% (26/50) TNBC, 31.0%
(13/42) Luminal A , 33.3% (5/15)
Luminal B and 50.9% (15/29) HER2-enriched were PTEN positive. The expression of
PD- L1(SP142) was positively
correlated with the expression of CTLA-4in TNBC
(Spearman=0.409, P<0.05), but negatively correlated with the expression of PTEN (Spearman=-0.318, P<0.05). Conclusion The positively
correlation betweenPD-L1(SP142)and CTLA-4 in TNBC
suggests that combined immunotherapy may benefit TNBC patients,
the negative correlation between PD-L1(SP142) andPTEN suggests that TNBC may suffer from double hits(immune escape and gene
mutation), so TNBC
is suitable for combining immunotherapy and targeted PTEN therapy.
